U.S. Biological Sample Collection Kits Market - By Product (Swabs, Viral Transport Media, Blood Collection Kits, Urine Collection Kits), Application (Diagnostics, Research), End-use (Hospitals and Clinics, Diagnostic Centers, Homecare) & Forecast, 2024 – 2032

U.S. Biological Sample Collection Kits Market Size

U.S. Biological Sample Collection Kits Market size was valued at USD 2.5 billion in 2023 and is expected to exhibit growth at a CAGR of 7.8% from 2024 to 2032. The rising usage of laboratory tests for precise disease diagnosis is a key factor driving the demand for the market.
 

With the increasing emphasis on early and accurate diagnosis, there is a growing reliance on advanced diagnostic tests that require high-quality biological samples. For instance, according to the American Clinical Laboratory Association (ACLA), approximately 13 billion laboratory tests are performed annually in the U.S., underscoring the critical role of lab testing in healthcare. The need for accurate and early diagnosis, particularly in the fields of personalized medicine, infectious disease testing, and chronic disease management, underscores the importance of reliable sample collection. With the market for clinical laboratory services expected to continue growing, the demand for high-quality biological sample collection kits is likely to remain robust.
 

Biological sample collection kits are specialized packages or containers designed to safely and efficiently collect, preserve, and transport various types of biological specimens for laboratory analysis. These kits are crucial in biomedical and clinical research, diagnostics, and healthcare settings where accurate and reliable analysis of biological samples is essential.
 

U.S. Biological Sample Collection Kits Market Trends

Increased investment in research and development within the biomedical and pharmaceutical sectors is driving the demand for advanced sample collection kits. Innovations in sample collection techniques are improving the accuracy, convenience, and reliability of biological sample collection.
 

• Systems that integrate sample collection with stabilization and transport media have been developed to ensure the integrity of samples from collection to analysis. Examples include DNA/RNA stabilization tubes that prevent nucleic acid degradation.
   
• These research and innovation are propelled by the high investment in the R&D activities. For instance, according to Research America, U.S. investment in medical and health R&D reached USD 245.1 billion in 2021, reflecting a continuous increase in research funding.
   
• Additionally, researchers are exploring the use of nanotechnology in medical devices to develop ultra-sensitive collection devices that can capture minute quantities of biomarkers from body fluids. These advancements aim to improve the early detection of diseases by enhancing the sensitivity and specificity of sample collection.
   
• Moreover, the development of customizable 3D-printed sample collection devices is underway. These devices can be tailored to specific patient needs and collection sites, offering a more personalized and precise approach to sample collection.
   
• Furthermore, the integration of IoT (Internet of Things) technology into sample collection kits is an emerging field. These smart systems can track and monitor the condition of samples in real-time, ensuring they remain within optimal conditions during transport and storage. Although still in development, this technology holds great promise for improving sample integrity. These advancements are driving continued growth and innovation in the biological sample collection kits market.
   

U.S. Biological Sample Collection Kits Market Analysis

Based on product, the U market is categorized into swabs, viral transport media, blood collection kits, urine collection kits, and other products. The swabs segment generated the highest revenue of USD 695.2 million in 2023.
 

• The significant volume of testing required for disease surveillance, contact tracing, and public health initiatives ensures a sustained and large-scale demand for swabs.
   
• Additionally, swabs are essential for collecting samples to diagnose various infectious diseases beyond COVID-19, such as influenza, respiratory syncytial virus (RSV), strep throat, and other respiratory infections.
   

Based on application, the U.S. biological sample collection kits market is classified into diagnostics, and research. The diagnostics segment dominated the market in 2023 with a market share of 69%.
 

• The continuous need to diagnose and monitor infectious diseases, including COVID-19, influenza, HIV, tuberculosis, and other bacterial or viral infections, drives significant demand for diagnostic testing.
   
• Furthermore, advances in diagnostic technologies, such as point-of-care testing (POCT), molecular diagnostics, and rapid tests, have made diagnostics more accessible and efficient. These technologies often require specialized sample collection kits and increase their demand in the market.
   

Based on end-use, the U.S. biological sample collection kits market is classified into hospitals and clinics, diagnostic centers, homecare, and other end-users. The hospitals and clinics segment dominated the market and is expected to grow at a pace of 7.6% CAGR between 2024 – 2032.
 

• Hospitals and clinics perform a broad spectrum of diagnostic testing, including blood testing, urine testing, swab testing, tissue biopsies, and more. This comprehensive range of services necessitates a constant supply of diverse sample collection kits.
   
• Moreover, in emergency and critical care settings, rapid diagnostic testing is essential. Hospitals, with their emergency departments and intensive care units (ICUs), require reliable and quick sample collection methods to diagnose and treat patients promptly, increasing their demand in these facilities.
   

U.S. Biological Sample Collection Kits Market Companies

As the demand for accurate sample collection kits escalates, market expansion, collaboration, and investment in advanced solutions become crucial strategies for industry players.
 

Prominent players operating in the biological sample collection kits industry include:

• Abbott Laboratories
• Becton, Dickinson and Company
• CTK Biotech, Inc.
• F. Hoffmann-La Roche Ltd
• Hardy Diagnostics
• Laboratory Corporation of America Holdings
• Lucence Health Inc.
• Medline Industries, Inc.
• Puritan Medical Products
• QIAGEN
• Thermo Fisher Scientific, Inc.
   

U.S. Biological Sample Collection Kits Industry News:

• In January 2024, Hardy became an authorized distributor of the U.S. based LifeSign rapid diagnostic tests. These kits are for laboratory and “Point of Care” use. This achievement will improve the company’s competitiveness in the market.

• In March 2021, Roche announced the launch of the DISCOVERY Green HRP kit, the comprehensive collection of modular-based detection kits that identify and profile biomarkers and cell populations in tissue-based research. This launch enabled the company to improve its awareness of the biological sample collection kits market and enabled more customer base.
   

The U.S. biological sample collection kits market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Swabs
  • Nasopharyngeal (NP) swabs
  • Oropharyngeal (OP) swabs
  • Nasal swabs
• Viral transport media
• Blood collection kits
• Urine collection kits
• Other products

Market, By Application 

• Diagnostics
• Research

Market, By End-use

• Hospitals and clinics
• Diagnostic centers
• Homecare
• Other end-users